title: Effect of Non-Hodgkin Lymphoma on Survival in Patients With Malignant Fibrous Histiocytoma, Kaposi Sarcoma, and Sebaceous Carcinoma: A SEER Population-Based Study.
abstract: OBJECTIVE
  To quantify the behavior of dermatofibrosarcoma protuberans (DFSP), malignant fibrous histiocytoma (MFH), Kaposi sarcoma (KS), and sebaceous carcinoma (SC) in patients with a history of non-Hodgkin lymphoma (NHL).
  
  
  METHODS
  Subjects with a diagnosis of DFSP, MFH, KS, or SC between 1990 and 2006 were identified in the Surveillance, Epidemiology, and End Results Program database. For each skin cancer type, the standardized mortality ratio (SMR) for death due to any cause and death due to skin cancer was estimated.
  
  
  RESULTS
  From 1990 through 2006, 25,357 skin cancers were identified: 4,192 DFSP, 6,412 MFH, 10,543 KS, and 4,222 SC. For patients with a history of non-CLL NHL, SMRs for death due to any cause were 1.45 (95% confidence interval [CI], 1.03-2.04; p = 0.04) for MFH, 2.90 (95% CI, 2.50-3.36; p < 0.001) for KS, and 3.25 (95% CI, 1.84-5.75; p < 0.001) for SC and SMRs for death due to skin cancer were 0.55 (95% CI, 0.23-1.31; p = 0.18) for MFH, 2.93 (95% CI, 2.49-3.43; p < 0.001) for KS, and 4.07 (95% CI, 1.28-12.94; p < 0.001) for SC.
  
  
  CONCLUSIONS
  Among patients with KS and SC, patients with a history of non-CLL NHL have a greater risk of overall and cause-specific death than expected.
authors.affiliation: *Division of Dermatologic Surgery, Mayo Clinic, Rochester, Minnesota; †Division of Hematology, Mayo Clinic, Rochester, Minnesota; ‡Division of Epidemiology, Mayo Clinic, Rochester, Minnesota; §Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota; ‖Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota.
authors.forename: Jerry D
authors.initials: JD
authors.lastname: Brewer
authors.forename: Tait D
authors.initials: TD
authors.lastname: Shanafelt
authors.forename: James R
authors.initials: JR
authors.lastname: Cerhan
authors.forename: Timothy G
authors.initials: TG
authors.lastname: Call
authors.forename: Amy L
authors.initials: AL
authors.lastname: Weaver
authors.forename: Clark C
authors.initials: CC
authors.lastname: Otley
mesh_terms: D018266:Adenocarcinoma, Sebaceous / Q000401:mortality*; D002423:Cause of Death; D018223:Dermatofibrosarcoma / Q000401:mortality*; D051677:Histiocytoma, Malignant Fibrous / Q000401:mortality*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin; D016609:Neoplasms, Second Primary / Q000401:mortality*; D012307:Risk Factors; D018426:SEER Program; D012514:Sarcoma, Kaposi / Q000401:mortality*; D012626:Sebaceous Gland Neoplasms / Q000401:mortality*; D012878:Skin Neoplasms / Q000401:mortality*; D014481:United States / Q000453:epidemiology